A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
This study tests an experimental cancer medication called TNG462, both on its own and combined with an immunotherapy drug, for people with advanced solid tumors. Researchers want to find the safest and most effective dose to help fight tumors that have a specific missing protein called MTAP.
You may be able to join if you are 18 or older, can handle daily activities with little help, and have an advanced solid tumor that has tested positive for the MTAP genetic change. You must have already tried available standard treatments and be free of severe active infections or other uncontrolled health issues.
You will receive the study medication, TNG462, by mouth, and some participants may also receive an immunotherapy medication called pembrolizumab. The doctors will closely monitor your health, how your body tolerates the treatment, and how your tumor responds.
This study is currently recruiting participants at locations in California, Colorado, and Florida in the United States. Up to 225 people will take part in this research.
- 1Testing a new targeted cancer pill called TNG462
- 2Requires tumors to have a specific genetic change called MTAP
- 3Currently recruiting patients at multiple medical centers in the US
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.